NCT06048523 Prospective Cohort Study of Neurogenetic Diseases
| NCT ID | NCT06048523 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Hospital, Bordeaux |
| Condition | Genetic Disease |
| Study Type | INTERVENTIONAL |
| Enrollment | 150 participants |
| Start Date | 2024-07-18 |
| Primary Completion | 2030-07 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 150 participants in total. It began in 2024-07-18 with a primary completion date of 2030-07.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Neurogenetic diseases (NGD) represent rare and hereditary forms of neurological diseases. The goal of CNGD is to create a one-window approach for NGDs, to facilitate and accelerate participation in research projects through deep phenotyping and the availability of low-cost biological samples for research teams. It is positioned as a true hub allowing new connections between clinical and basic research teams and ultimately as an incubator for translational projects for NGDs, in order to be able to initiate therapeutic trials, the ultimate objective of clinical and translational research.
Eligibility Criteria
Inclusion Criteria: * Patient-specific inclusion criteria * Age ≥ 6 years * Patient with a molecularly identified NGD o Specific inclusion criteria for controls * For the 10 controls with lumbar puncture (LP): person who performed an LP for medical reasons and who consented to participate in the collection of biological samples * Age ≥ 18 years * Person matched in age (+/- 5 years) and sex to adult patient with NGD at the time of collection Exclusion Criteria: * Participation in an interventional clinical trial that may interfere with our study * Refusal of blood collection * Pregnant and breastfeeding women * Only for patients performing LP: Contraindication to LP * Specific non-inclusion criteria for controls: Criterion of a neurodegenerative or inflammatory pathology of the central nervous system
Contact & Investigator
Chloe ANGELINI, MD
PRINCIPAL INVESTIGATOR
University Hospital, Bordeaux
Frequently Asked Questions
Who can join the NCT06048523 clinical trial?
This trial is open to participants of all sexes, aged 6 Years or older, studying Genetic Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06048523 currently recruiting?
Yes, NCT06048523 is actively recruiting participants. Contact the research team at chloe.angelini@chu-bordeaux.fr for enrollment information.
Where is the NCT06048523 trial being conducted?
This trial is being conducted at Bordeaux, France.
Who is sponsoring the NCT06048523 clinical trial?
NCT06048523 is sponsored by University Hospital, Bordeaux. The principal investigator is Chloe ANGELINI, MD at University Hospital, Bordeaux. The trial plans to enroll 150 participants.